Skip to main content
Top
Published in: Journal of Gastroenterology 1/2012

01-01-2012 | Original Article—Alimentary Tract

Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes

Authors: Naoki Yoshimura, Tokuma Tadami, Takaaki Kawaguchi, Minako Sako, Hiroshi Yoshimoto, Toshihiko Yamaka, Masakazu Takazoe

Published in: Journal of Gastroenterology | Issue 1/2012

Login to get access

Abstract

Background

Hitherto, therapeutic depletion of granulocytes and monocytes by adsorption (GMA) has been associated with significant and insignificant efficacy in patients with ulcerative colitis (UC). Further, the processed blood volume in one GMA session has been fixed at 30 mL/min × 60 min, regardless of patients’ body weight (BW). We were interested to see the efficacy and safety of GMA when administered in relation to patients’ BW.

Methods

Sixty patients were randomly assigned to the routine GMA (n = 30) and to GMA adjusted to patients’ BW, 60 mL/kg (n = 30). GMA was done with the Adacolumn, up to 10 sessions over 10 weeks. At entry and 1 week post last GMA, patients were clinically and endoscopically evaluated. Remission was defined as clinical activity index (CAI) ≤4, whereas mucosal remission was defined as endoscopic index (EI) ≤3.

Results

In the BW group, the processed volume/session was 3,260 ± 581 versus 1,800 mL in the routine group (P < 0.001). In the BW group, 25 of 30 patients (83.3%) achieved remission versus 19 of 30 patients (63.3%) in the routine group. The average CAI in the BW group fell from 9.6 ± 2.6 to 2.3 ± 2.1 versus from 9.1 ± 2.4 to 4.0 ± 2.1 (P < 0.05) in the routine group. Similarly, the EI in the BW group fell from 9.4 ± 1.3 to 2.1 ± 2.1 versus from 9.2 ± 1.8 to 4.5 ± 2.3 (P < 0.01).

Conclusions

GMA adjusted to patients’ BW and at a vastly greater processed volume produces significantly higher efficacy as compared with the routine GMA protocol. Further, in this study, up to twofold higher processed volume caused no safety concern.
Literature
1.
go back to reference Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12:S3–9.PubMedCrossRef Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12:S3–9.PubMedCrossRef
2.
go back to reference Allison MC, Dhillon AP, Lewis WG, Pounder RE, editors. Inflammatory bowel disease. London: Mosby; 1998. p. 9–95. Allison MC, Dhillon AP, Lewis WG, Pounder RE, editors. Inflammatory bowel disease. London: Mosby; 1998. p. 9–95.
3.
go back to reference Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis. 2000;6:48–57.PubMedCrossRef Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis. 2000;6:48–57.PubMedCrossRef
4.
go back to reference van Dullemen HM, van Deventer SJ, Hommes DW. Treatment of Crohn’s disease with anti-tumour necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129–35.PubMedCrossRef van Dullemen HM, van Deventer SJ, Hommes DW. Treatment of Crohn’s disease with anti-tumour necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129–35.PubMedCrossRef
5.
go back to reference Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.PubMedCrossRef Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.PubMedCrossRef
6.
go back to reference McCarthy DA, Rampton DS, Liu Y-C. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol. 1991;86:489–93.PubMedCrossRef McCarthy DA, Rampton DS, Liu Y-C. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol. 1991;86:489–93.PubMedCrossRef
7.
go back to reference Tibble JA, Sigthorsson G, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15–22.PubMedCrossRef Tibble JA, Sigthorsson G, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15–22.PubMedCrossRef
8.
go back to reference Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood. 1989;74:2527–34.PubMed Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood. 1989;74:2527–34.PubMed
9.
go back to reference Belge KU, Dayyani F, Horelt A. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol. 2002;168:3536–42.PubMed Belge KU, Dayyani F, Horelt A. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol. 2002;168:3536–42.PubMed
10.
go back to reference Hanai H, Iida T, Takeuchi K, Watanabe F, Yamada M, Kikuyama M, et al. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Am J Gastroenterol. 2008;103:1210–6.PubMedCrossRef Hanai H, Iida T, Takeuchi K, Watanabe F, Yamada M, Kikuyama M, et al. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Am J Gastroenterol. 2008;103:1210–6.PubMedCrossRef
11.
go back to reference Cohen RD. Treating ulcerative colitis without medications—“Look Mom, no drugs!” Gastroenterology. 2005;128:235–6.PubMedCrossRef Cohen RD. Treating ulcerative colitis without medications—“Look Mom, no drugs!” Gastroenterology. 2005;128:235–6.PubMedCrossRef
12.
go back to reference Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Vandervoort MK, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135:400–9.PubMedCrossRef Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Vandervoort MK, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135:400–9.PubMedCrossRef
13.
go back to reference Saniabadi AR, Hanai H, Takeuchi K, Umemura K, Nakashima M, Adachi T, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial. 2003;7:48–59.PubMedCrossRef Saniabadi AR, Hanai H, Takeuchi K, Umemura K, Nakashima M, Adachi T, et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial. 2003;7:48–59.PubMedCrossRef
14.
go back to reference Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Matsueda K, Munakata A, et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher. 2001;16:1–9.PubMedCrossRef Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Matsueda K, Munakata A, et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher. 2001;16:1–9.PubMedCrossRef
15.
go back to reference Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled study. Clin Gastroenterol Hepatol. 2003;1:28–35.PubMedCrossRef Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled study. Clin Gastroenterol Hepatol. 2003;1:28–35.PubMedCrossRef
16.
go back to reference Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective granulocytes and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci. 2004;49:565–71.PubMedCrossRef Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective granulocytes and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci. 2004;49:565–71.PubMedCrossRef
17.
go back to reference Saniabadi AR, Hanai H, Suzuki Y, Ohmori T, Sawada K, Yoshimura N, et al. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher. 2005;20:171–84. Saniabadi AR, Hanai H, Suzuki Y, Ohmori T, Sawada K, Yoshimura N, et al. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher. 2005;20:171–84.
18.
go back to reference Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Ahlborg N, et al. Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J Colorectal Dis. 2006;21:493–504.PubMedCrossRef Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Ahlborg N, et al. Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J Colorectal Dis. 2006;21:493–504.PubMedCrossRef
19.
go back to reference Maiden L, Takeuchi K, Baur R, Bjarnason I, O’Donohue J, Forgacs I, et al. Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis. 2008;14:1413–8.PubMedCrossRef Maiden L, Takeuchi K, Baur R, Bjarnason I, O’Donohue J, Forgacs I, et al. Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis. 2008;14:1413–8.PubMedCrossRef
20.
go back to reference Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis. 2004;10:251–7.PubMedCrossRef Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis. 2004;10:251–7.PubMedCrossRef
21.
go back to reference Yamamoto T, Umegae S, Kitagawa T. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther. 2004;20:783–92.PubMedCrossRef Yamamoto T, Umegae S, Kitagawa T. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther. 2004;20:783–92.PubMedCrossRef
22.
go back to reference Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, et al. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther. 2004;20:1347–52.PubMedCrossRef Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, et al. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther. 2004;20:1347–52.PubMedCrossRef
23.
go back to reference Suzuki Y, Yoshimura N, Fukuda K, Shirai K, Saito Y, Saniabadi AR. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci. 2006;51:2031–8.PubMedCrossRef Suzuki Y, Yoshimura N, Fukuda K, Shirai K, Saito Y, Saniabadi AR. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci. 2006;51:2031–8.PubMedCrossRef
24.
go back to reference Tanaka T, Okanobu H, Yoshimi S, Murakami E, Kogame A, Imagawa H, et al. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients. Dig Liver Dis. 2008;40:731–6.PubMedCrossRef Tanaka T, Okanobu H, Yoshimi S, Murakami E, Kogame A, Imagawa H, et al. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients. Dig Liver Dis. 2008;40:731–6.PubMedCrossRef
25.
go back to reference Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion. 2004;70:36–44.PubMedCrossRef Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion. 2004;70:36–44.PubMedCrossRef
26.
go back to reference Hibi T, Sameshima Y, Sekiguchi Y, Hisatome Y, Maruyama F, Moriwaki K, et al. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis. 2009;41:570–7.PubMedCrossRef Hibi T, Sameshima Y, Sekiguchi Y, Hisatome Y, Maruyama F, Moriwaki K, et al. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis. 2009;41:570–7.PubMedCrossRef
27.
go back to reference Rachmilewitz D, on behalf of an international study group. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J. 1989;298:82–6.CrossRef Rachmilewitz D, on behalf of an international study group. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J. 1989;298:82–6.CrossRef
28.
go back to reference Saniabadi AR, Hanai H, Fukunaga K, Sawada K, Shima C, Bjarnason I, et al. Therapeutic leucocytapheresis for inflammatory bowel disease. Transf Apher Sci. 2007;37:191–200.CrossRef Saniabadi AR, Hanai H, Fukunaga K, Sawada K, Shima C, Bjarnason I, et al. Therapeutic leucocytapheresis for inflammatory bowel disease. Transf Apher Sci. 2007;37:191–200.CrossRef
29.
30.
go back to reference D’Haens G, Lemmens L, Geboes K. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology. 2001;120:1323–9.PubMedCrossRef D’Haens G, Lemmens L, Geboes K. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology. 2001;120:1323–9.PubMedCrossRef
31.
go back to reference Hanauer SB. Can cyclosporine go it alone in severe ulcerative colitis. Curr Gastroenterol Rep. 2001;3:455–6.PubMedCrossRef Hanauer SB. Can cyclosporine go it alone in severe ulcerative colitis. Curr Gastroenterol Rep. 2001;3:455–6.PubMedCrossRef
32.
go back to reference Taffet SL, Das KM. Sulfasalazine-adverse effects and desensitization. Dig Dis Sci. 1983;28:833–42.PubMedCrossRef Taffet SL, Das KM. Sulfasalazine-adverse effects and desensitization. Dig Dis Sci. 1983;28:833–42.PubMedCrossRef
33.
go back to reference Tanaka T, Okanobu H, Kuga Y, Yoshifuku Y, Fujino H, Miwata T, et al. Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis. Gastroenterol Clin Biol. 2010;34:687–95.PubMedCrossRef Tanaka T, Okanobu H, Kuga Y, Yoshifuku Y, Fujino H, Miwata T, et al. Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis. Gastroenterol Clin Biol. 2010;34:687–95.PubMedCrossRef
34.
go back to reference Saniabadi AR, Hanai H. Therapeutic apheresis from the early civilizations to the twenty-first century. Gastroenterol Clin Biol. 2010;34:645–8.PubMedCrossRef Saniabadi AR, Hanai H. Therapeutic apheresis from the early civilizations to the twenty-first century. Gastroenterol Clin Biol. 2010;34:645–8.PubMedCrossRef
35.
go back to reference Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K, Suzuki Y, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009;104:2990–5.PubMedCrossRef Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K, Suzuki Y, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009;104:2990–5.PubMedCrossRef
36.
go back to reference Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, et al. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163:50–8.PubMedCrossRef Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, et al. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163:50–8.PubMedCrossRef
37.
go back to reference Kanke K, Nakano M, Hiraishi H, Terano A. Evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liv Dis. 2004;36:512–8.CrossRef Kanke K, Nakano M, Hiraishi H, Terano A. Evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liv Dis. 2004;36:512–8.CrossRef
Metadata
Title
Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes
Authors
Naoki Yoshimura
Tokuma Tadami
Takaaki Kawaguchi
Minako Sako
Hiroshi Yoshimoto
Toshihiko Yamaka
Masakazu Takazoe
Publication date
01-01-2012
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 1/2012
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-011-0464-0

Other articles of this Issue 1/2012

Journal of Gastroenterology 1/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.